IJR News — today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Elections
Genius — OpenServe
Trending
Healing of Lydia Gouardo at Lourdes
Good News
— FROM 1978
Multiple sclerosis healed
0
Share
The Healing of Anne-Marie Ménage's Relative
Good News
— FROM 1947
Multiple sclerosis cured
0
Share
The Healing of Jean-Pierre Bély's Sister
Good News
— FROM 1987
Multiple sclerosis cured
0
Share
Healing of Jean-Pierre Bély at Lourdes
Good News
— FROM 1987
Multiple sclerosis cured
0
Share
IJR
Cyberattack Turns Hundreds Of Grocery Coolers Into Saunas As Military Stores’ Meltdown Remains A Mystery
Dylan Kresak · 3 min · 12h
Christina Applegate Talks Finishing Her Netflix Show While Struggling With Multiple Sclerosis
Reporting
— Nov 3, 2022
Actress Christina Applegate opened up about her multiple sclerosis diagnosis. In an interview with The New York Times published Tuesday, Applegate spoke about the warning signs of her illness which included a tingling…
0
Share
AP Top 25 College Football Teams
Ranking
College football fans argue endlessly over which programs deserve the top spots in the AP Poll based on wins, schedule strength, and legacy.
Share
MS Battle Leaves Christina Applegate Bedridden but Focused on Daughter
x/the-new-york-post
— Feb 24, 2026
Christina Applegate says daily life has narrowed to a painful routine as she continues her fight with multiple sclerosis. According to Page Six , the actress shared that she is largely confined to her bed, pushing…
0
Share
Actress Selma Blair Talks Her Decision to Leave ‘Dancing With the Stars’ Over Health Concerns
Reporting
— Oct 18, 2022
Actress Selma Blair addressed her exit from “Dancing with the Stars” due to complications with multiple sclerosis. After Monday night’s show, Blair told Page Six , “This was a really emotional night for me. Because it…
0
Share
Novartis MS pill beats Aubagio in two large phase 3 trials
x/novartis
— Sep 1, 2026
Novartis reported positive Phase 3 REMODEL-1 and REMODEL-2 results for the BTK inhibitor remibrutinib in relapsing multiple sclerosis, showing lower annualized relapse rate and meaningful reductions in disability progression versus teriflunomide and prompting worldwide regulatory filings. With remibrutinib already approved for chronic spontaneous urticaria as Rhapsido, the drug’s MS potential could become a major growth driver given its favorable safety profile and strong early sales signals.
+6
+1
2
Share
Rachel Meyers
Teriflunomide isn't the toughest comparator out there, would like to see how remibrutinib stacks up against some of the stronger existing MS drugs before getting too excited.
